Back to BAX Stock Lookup

Baxter (BAX) – Press Releases

Jul 2, 2015 08:00 AM Baxter Announces Early Results of Debt Tender Offers
Jul 1, 2015 04:46 PM Baxter Announces Pricing of Debt Tender Offers
Jun 25, 2015 03:18 PM MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer
Jun 25, 2015 07:00 AM U.S. FDA Grants Priority Review for MM-398 New Drug Application
Jun 24, 2015 09:00 AM Baxalta Reports Continued Progress on Phase 1/2 Clinical Trial of BAX335, Investigational Gene Therapy Treatment for Hemophilia B
Jun 22, 2015 06:30 AM Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
Jun 19, 2015 06:13 PM The Priceline Group Set to Join the S&P 100; Baxalta to Join the 500; Other Changes to S&P MidCap 400 & S&P SmallCap 600
Jun 19, 2015 09:00 AM Baxalta Demonstrates Commitment to Innovation in Hemophilia and Blood Disorders at ISTH 2015 Congress
Jun 19, 2015 08:00 AM Baxalta Announces Pricing of $5 Billion Private Placement Notes Offering
Jun 18, 2015 08:30 AM Baxter Announces Debt Tender Offers
Jun 12, 2015 03:30 AM Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
Jun 11, 2015 05:00 PM Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
Jun 10, 2015 09:00 AM Baxter’s Commitment to Innovative Programs and Advancing Its Sustainability Priorities Featured in Sixteenth Report
Jun 10, 2015 01:30 AM CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
Jun 9, 2015 05:00 PM Baxter Announces Effectiveness of Baxalta Form 10 Registration Statement
Jun 5, 2015 04:30 PM Baxter’s Board of Directors Approves Separation of Baxalta and Declares Special Dividend of Baxalta Stock
Jun 1, 2015 04:12 PM Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
Jun 1, 2015 09:00 AM Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development Announce the Formation of Vitesse Biologics, LLC, a Company Structured to Accelerate Therapeutic Innovation
Jun 1, 2015 09:00 AM Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation
May 31, 2015 11:20 PM PharmaEngine Announces Filing New Drug Application (NDA) of MM-398 (PEP02) to Taiwan FDA as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
May 30, 2015 07:30 AM Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
May 29, 2015 07:00 AM Baxter Presents Data Demonstrating Remote Technology May Help Reduce Barriers to Home Therapy
May 28, 2015 04:15 PM Baxter and Baxalta Executives to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
May 21, 2015 09:00 AM Baxter BioScience Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency
May 18, 2015 08:30 AM Baxter and Baxalta Highlight Business Strategies at Investor Conferences
May 15, 2015 05:26 PM Baxter Receives U.S. FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain, Facility for the U.S. Market
May 13, 2015 09:00 AM Economists Anthony Culyer and Alan Maynard Named Co-Recipients of the 2015 William B. Graham Prize for Health Services Research
May 12, 2015 09:00 AM Baxter BioScience to Expand Global Oncology Footprint with Acquisition of Oncaspar® Portfolio for Leukemia
May 11, 2015 04:30 PM Baxter to Host May 2015 Investor Conferences
May 5, 2015 08:55 AM Baxter Declares Quarterly Dividend
May 4, 2015 10:00 AM PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients
May 4, 2015 09:00 AM Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
May 1, 2015 09:15 AM Baxter to Host May 2015 Investor Conferences
Apr 27, 2015 09:00 PM PharmaEngine Announces Merrimack Completed MM-398 (PEP02) New Drug Application Submission to U.S. FDA
Apr 27, 2015 07:00 AM Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 23, 2015 07:00 AM Baxter Reports First Quarter Financial Results That Exceed Guidance
Apr 22, 2015 01:30 AM CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
Apr 21, 2015 04:15 PM Baxter to Webcast Annual Meeting of Shareholders
Apr 21, 2015 09:00 AM Baxter Supports IPOPI Initiative to Improve Global Care of Primary Immunodeficiencies During 5th Annual World PI Week
Apr 17, 2015 04:30 PM Full Data on Baxter’s Investigational Recombinant Treatment BAX 111 Supports Potential Role to Treat von Willebrand Disease
Apr 16, 2015 09:00 AM Baxter Submits Application to Japan’s MHLW for Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A
Apr 15, 2015 08:00 AM Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement
Apr 7, 2015 04:15 PM Baxter International First Quarter 2015 Financial Results Conference Call
Apr 2, 2015 08:00 AM Baxter and Laboratoire Aguettant Announce Global Collaboration for Parenteral Nutrition Trace Elements
Apr 1, 2015 08:00 AM Baxter Completes CE Mark Approval for HOMECHOICE CLARIA Automated Peritoneal Dialysis System with SHARESOURCE
Mar 30, 2015 09:00 AM Baxter Expands Access to Healthcare Through Collaborations and Charitable Giving
Mar 20, 2015 03:46 PM Fitch Maintains Baxter International on Rating Watch Negative
Mar 13, 2015 09:00 AM Baxter BioScience Announces Positive Phase III Results for BAX 817, Investigational Recombinant Treatment for Hemophila A and B Patients with Inhibitors
Mar 9, 2015 07:00 AM CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis

Back to BAX Stock Lookup